Under construction – not a live service
Sign in
Taking people in PolandPhase 3

Long-term safety of dapirolizumab pegol in people with lupus

Tests dapirolizumab pegol's long-term safety in people with systemic lupus erythematosus.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

Key facts

Where
Bialystok, Bydgoszcz, Cracow, Katowice, Lublin, Poznan, Warsaw, and Wroclaw, PolandSee the 17 sites
Phase
Phase 3

Where in Poland

  • INTER CLINIC Piotr Adrian KlimiukBialystok, PolandTaking people
  • Szpital Uniwersytecki nr 2 im dr Jana Biziela w BydgoszczyBydgoszcz, PolandTaking people
  • Centrum Medyczne Plejady Magdalena Celinska Loewenhoff Michal Zolnowski sp.k.Cracow, PolandTaking people
  • Pratia S.A.Cracow, PolandTaking people
  • Pratia S.A.Katowice, PolandTaking people
  • Provita Sp z o oKatowice, PolandTaking people
  • Reumed Sp. z o.o.Lublin, PolandTaking people
  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w LublinieLublin, PolandTaking people
  • Medyczne Centrum Hetmańska Piotr LeszczyńskiPoznan, PolandTaking people
  • Ortopedyczno - Rehabilitacyjny Szpital Kliniczny im. Wiktora Degi Uniwersytetu Medycznego im. Karola Marcinkowskiego w PoznaniuPoznan, PolandTaking people
  • Prywatna Praktyka Lekarska Prof. dr hab. med. Pawel HrycajPoznan, PolandTaking people
  • Twoja Przychodnia Poznanskie Centrum Medyczne Sp. z o.o.Poznan, PolandTaking people
  • Klinika Reuma Park Sp. z o.o. S.K.Warsaw, PolandTaking people
  • Medicover Integrated Clinical Services Sp. z o.o.Warsaw, PolandTaking people
  • Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory ReicherWarsaw, PolandTaking people
  • Reum Medica Bozena Kowalewska Marek ZawadzkiWroclaw, PolandTaking people
  • Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we WroclawiuWroclaw, PolandTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
UCB Biopharma SRL
Trial code
NCT04976322EU 2023-506368-14-00
Record updated
15 October 2026
Original description
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.Read full original descriptionShow less

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

Inclusion: The participant could, in the opinion of the Investigator, benefit from long-term dapirolizumab pegol (DZP) treatment; The participant completed one of the parent studies within 4 weeks prior to entry to this study.

Exclusion: Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing malignancies at the start of the study.

ClinicalTrials.gov NCT04976322 · EU CTIS 2023-506368-14-00